Boc-D-天冬氨酸 4-烯丙酯 | 207120-58-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天冬氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Boc-D-天冬氨酸 4-烯丙酯
• 中文别名: BOC-D-天冬氨酸4-烯丙酯；Boc-D-天冬氨酸4-烯丙酯；BOC-D-天冬氨酸 4-烯丙酯
• 英文名称: (R)-4-(allyloxy)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid
• 英文别名: N-(tert-butoxycarbonyl)-(2R)-aspartic acid β-allyl ester；β-allyl (2R)-N-(tert-butoxycarbonyl)aspartate ester；N-Boc-(2R)-aspartic acid β-allyl ester；2-tert-butoxycarbonylamino-succinic acid 4-allyl ester；Boc-D-asp(oall)-OH；(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-prop-2-enoxybutanoic acid
• CAS: 207120-58-9
• 化学式: C₁₂H₁₉NO₆
• 分子量: 273.286
• InChiKey: WZMNSEVEWIDHND-MRVPVSSYSA-N

物化性质

• 沸点：
  437.6±45.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-d-asp(oall)-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-d-asp(oall)-oh
CAS number: 207120-58-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H19NO6
Molecular weight: 273.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Boc-D-天冬氨酸 4-烯丙酯 在 4-二甲氨基吡啶 、 迭氮酸 、 偶氮二甲酸二异丙酯 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 三甲基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 异丙醇 、 甲苯 为溶剂， 反应 34.5h， 生成 allyl 2-((2R,5S)-4-benzyl-5-(((tert-butoxycarbonyl)amino)methyl)-3,6-dioxopiperazin-2-yl)acetate
  参考文献：
  名称：

  包含新型双功能整合素配体的双功能二酮哌嗪支架的环状RGD拟肽。

  摘要：

  描述了八个双功能二酮哌嗪（DKP）支架的合成。它们正式衍生自2,3-二氨基丙酸和天冬氨酸（DKP - 1 – DKP - 7）或谷氨酸（DKP - 8），具有胺和羧酸官能团。支架在两个立体中心的构型和在二酮哌嗪氮原子上的取代不同。将双功能二酮哌嗪引入了八个具有Arg-Gly-Asp（RGD）序列的环状拟肽中。将所得的肽模拟RGD筛选的能力抑制生物素化的玻连蛋白结合到纯化的整α v β3和α v β 5，其参与肿瘤血管生成。从反式DKP支架（DKP ‐ 2 – DKP ‐ 8）衍生的RGD拟肽获得了纳摩尔IC 50值。通过水溶液中的1 H NMR光谱实验（VT-NMR和NOESY光谱）和Monte Carlo /随机动力学（MC / SD）模拟对环状RGD拟肽进行构象研究，结果表明，亲和力最高的配体具有分子内明确定义的优选构象氢键转弯基序和RGD序列的扩展排列[Cβ（Arg）Cβ（Asp）平均距离≥8

  DOI：

  10.1002/chem.201200457
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 β-allyl (2R)-aspartate ester hydrochloride 在 水 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 18.0h， 以91%的产率得到Boc-D-天冬氨酸 4-烯丙酯
  参考文献：
  名称：

  基于结节蛋白和微囊藻毒素毒素结构的丝氨酸-苏氨酸蛋白磷酸酶抑制剂的设计和制备。第三部分

  摘要：

  结节菌素和微囊藻毒素是复杂的天然环状异肽肝毒素，可作为真核丝氨酸-苏氨酸蛋白磷酸酶PP1和PP2A的亚纳摩尔抑制剂，这些酶密切参与控制细胞代谢。以前，我们描述了剥离的结核菌素类似物的溶液相合成。环[-β-Ala-（R）-Glu-α-OMe-γ-Sar-（R）-Asp-α-OMe-β-（S）-Phe-] 3和环[-（3 R）- 3-羟甲基-β-Ala-（R）-Glu-α-OMe-γ-Sar-（R）-Asp-α-OMe-β-（S）-Phe-] 5。综合策略旨在允许宏环化后的阐述。在这里，我们研究了引入多样性并实现大环内酰胺化的替代方法，并比较了大环化合物的固相和固相肽合成的相对效率。大环环{-[（（2 R）-α-4-苄基哌啶基酰胺基-Asp] -β-[（R）-Glu ] -Sar -[（R -Asp ）-β-]大环的合成及生物学活性（S）-Phe-} 29和环{-（2 S）-Phe-[（2 R

  DOI：

  10.1039/b100401h

文献信息

• Synthesis and Biological Evaluation (in Vitro and in Vivo) of Cyclic Arginine–Glycine–Aspartate (RGD) Peptidomimetic–Paclitaxel Conjugates Targeting Integrin α_Vβ₃
  作者：Raffaele Colombo、Michele Mingozzi、Laura Belvisi、Daniela Arosio、Umberto Piarulli、Nives Carenini、Paola Perego、Nadia Zaffaroni、Michelandrea De Cesare、Vittoria Castiglioni、Eugenio Scanziani、Cesare Gennari

  DOI：10.1021/jm301058f

  日期：2012.12.13

  A small library of integrin ligand–paclitaxel conjugates 10–13 was synthesized with the aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytotoxic drug. All the paclitaxel–RGD constructs 10–13 inhibited biotinylated vitronectin binding to the purified αVβ3 integrin receptor at low nanomolar concentration and showed in vitro cytotoxic activity against a

  整联配体-紫杉醇结合体的一小库10 - 13用使用肿瘤归巢的目的合成环[DKP-RGD]对于细胞毒性药物的位点定向递送拟肽。所有的紫杉醇-RGD构造10 - 13受抑制生物素化的玻连蛋白结合到纯化的α V β 3整联在低纳摩尔浓度受体和体外细胞毒活性表现出抗类似于紫杉醇的人肿瘤细胞系组成的小组。在这些细胞系中，顺铂耐药的IGROV-1 / PT1细胞表达高水平的整合素α V β 3，使它们具有吸引力，可以在体内模型中进行测试。环[DKP - f 3-RGD] -PTX 11在生理溶液以及人和鼠血浆中均显示出足够的稳定性，是体内测试的良好候选者。在针对裸鼠异种移植的IGROV-1 / Pt1人卵巢癌的靶向肿瘤实验中，尽管使用的紫杉醇摩尔剂量较低（约一半），但与紫杉醇相比，化合物11的活性更高。
• PYRIDINONYL PDK1 INHIBITORS
  申请人：Lind Kenneth Egnard

  公开号：US20100144730A1

  公开（公告）日：2010-06-10

  The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.

  本发明提供了吡啶基PDK1抑制剂及其使用方法，用于治疗癌症。
• WO2008/5457
  申请人：——

  公开号：——

  公开（公告）日：——
• US8778977B2
  申请人：——

  公开号：US8778977B2

  公开（公告）日：2014-07-15
• US9873693B2
  申请人：——

  公开号：US9873693B2

  公开（公告）日：2018-01-23